Phaseline

Companies › Avalyn Pharma

Avalyn Pharma: clinical trials, targets and expected readouts

2 active drug programs in 8 registered trials: 4 Phase 2, 3 Phase 1, 1 Phase 3; Immunology, Respiratory, Cardiovascular, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Nintedanib (AP02)
Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor
PDGFRB, PDGFRA, FLT1, FLT4, KDRPhase 2Idiopathic Pulmonary Fibrosis (IPF); Systemic Sclerosis; Telangiectasia, Hereditary Hemorrhagic; Non Small Cell Lung Cancer …Dec 2026
AP01
Pirfenidone; antifibrotic agent
–Phase 2Pulmonary Fibrosis; Progressive Pulmonary FibrosisJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03377023Nintedanib (AP02)Phase 1Non Small Cell Lung CancerOncologyNov 2023
NCT06071013Nintedanib (AP02)Phase 1Non-small Cell Lung CancerOncologyAug 2026
NCT07194382Nintedanib (AP02)Phase 2Idiopathic Pulmonary Fibrosis (IPF)RespiratoryDec 2026
NCT04976036Nintedanib (AP02)Phase 2Telangiectasia, Hereditary HemorrhagicCardiovascularDec 2026
NCT03513484Nintedanib (AP02)Phase 1Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2AOncologyJan 2027
NCT06329401AP01Phase 2Pulmonary FibrosisImmunologyJun 2027
NCT06297096Nintedanib (AP02)Phase 3Systemic SclerosisImmunologyDec 2027
NCT06951217AP01Phase 2Progressive Pulmonary FibrosisRespiratoryDec 2031

From the company's SEC filings

Cash and short-term investments of $352m on 2026-06-30; operating cash outflow about $113m a year; runway about 37 months at that burn, to Aug 2029; 4 of 5 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PDGFRB (1) PDGFRA (1) FLT1 (1) FLT4 (1) KDR (1)

Companies with the same targets

Hutchmed Mannkind Betta Pharmaceuticals Chia Tai Tianqing Pharmaceutical Group AstraZeneca Jiangsu HengRui Medicine Advenchen Laboratories Merck & Co. (MSD) Takeda AO GENERIUM

Companies built like this

Enanta Pharmaceuticals Cumberland Pharmaceuticals Prana Therapies Enveda Therapeutics Palisade Bio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.